Lexicon Pharmaceuticals unveils new data on cardiovascular SGLT1/2 inhibitor

Lexicon Pharmaceuticals unveils new data on cardiovascular SGLT1/2 inhibitor
@LexPharma: Lexicon unveils new heart data

Lexicon Pharmaceuticals is set to present new data regarding their investigational SGLT1/2 inhibitor at the American Heart Association's Scientific Sessions this weekend.

The focus of the presentation will be the inhibitor's effect in reducing major cardiovascular events, marking a significant advancement in cardiovascular health research. This new data could have profound implications for the development of future treatments aimed at mitigating cardiovascular risks. Lexicon is leveraging this research to potentially enhance therapeutic strategies for patients suffering from heart-related conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.